Your browser doesn't support javascript.
loading
Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors.
Shen, Jie; Yan, Jing; Du, Juan; Li, Xiaoqin; Wei, Jia; Liu, Qin; Yong, Hongmei; Wang, Xiaolu; Chang, Xiaofeng; Ding, Zhou; Sun, Wu; Liu, Chenxi; Zhu, Sihui; Guo, Jingyi; Li, Huajun; Liu, Ying; Zhang, Wulou; Liu, Zonghang; Li, Rutian; Liu, Baorui.
Affiliation
  • Shen J; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Yan J; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Du J; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Li X; Department of Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Wei J; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Liu Q; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Yong H; Department of Oncology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, China.
  • Wang X; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Chang X; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Ding Z; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Sun W; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Liu C; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Zhu S; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Guo J; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Li H; Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
  • Liu Y; Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
  • Zhang W; Department-II of General Surgery, Nanjing Jiangbei Hospital, Nanjing, China.
  • Liu Z; Department-II of General Surgery, Nanjing Jiangbei Hospital, Nanjing, China.
  • Li R; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Liu B; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Front Immunol ; 14: 1133689, 2023.
Article in En | MEDLINE | ID: mdl-37056765
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Year: 2023 Type: Article